Welcome to our dedicated page for ALNYLAM PHARMACEUTICALS SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals reported a strong turnaround for the quarter ended March 31, 2026. Total revenues rose to $1,167,175,000 from $594,189,000 a year earlier, driven mainly by net product revenues of $1,036,127,000, with AMVUTTRA contributing $889,931,000.
The company moved from a net loss of $18,251,000 to net income of $205,991,000, or $1.51 per diluted share, as higher sales outpaced increased research and development and selling, general and administrative expenses. Operating income rose to $268,636,000 from $18,077,000.
Alnylam ended the quarter with cash, cash equivalents and marketable debt securities totaling about $3.01 billion and total assets of $5,129,547,000. Stockholders’ equity increased to $1,075,380,000, while the company continued to carry convertible debt and significant liabilities related to the sale of future royalties and development funding.
Alnylam Pharmaceuticals reported a very strong first quarter of 2026, driven by its transthyretin (TTR) franchise. Total revenues nearly doubled to $1.17 billion, with net product revenues of $1.04 billion, up 121% from the same quarter in 2025.
The company swung from a GAAP net loss of $18.3 million in Q1 2025 to GAAP net income of $206.0 million, and non‑GAAP net income rose to $273.0 million. AMVUTTRA generated $889.9 million in sales, and total TTR net product revenues reached $910.4 million, a 153% increase. Rare disease products GIVLAARI and OXLUMO added $125.7 million, up 15%.
Alnylam reiterated its full‑year 2026 guidance, including total net product revenues of $4.9–$5.3 billion and non‑GAAP R&D and SG&A expenses of $2.7–$2.8 billion, while highlighting broad pipeline progress and upcoming clinical readouts in the second half of 2026.
Vanguard Capital Management reported beneficial ownership of 7,104,536 shares of Alnylam Pharmaceuticals common stock, representing 5.35% of the class as of 03/31/2026. The filing shows Vanguard has sole dispositive power over 7,104,536 shares and sole voting power for 1,157,830 shares. The filing is signed by Ashley Grim on 04/29/2026.
Alnylam Pharmaceuticals’ Chief Human Resources Officer Melissa McLaughlin reported routine share sales tied to equity compensation taxes.
The Form 4 shows a total sale of 3,910 shares of common stock on April 2 and 6, 2026, executed automatically under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding on vested restricted stock units. After these transactions, she holds 9,443 shares directly. The filing notes the sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on December 16, 2025, indicating they were scheduled in advance rather than opportunistic trades.
Alnylam Pharmaceuticals executive Melissa McLaughlin, Chief Human Resources Officer, reported her equity holdings in the company. She directly holds 13,353 shares of common stock, including restricted stock units that will convert into shares over time.
She also holds a stock option covering 3,567 shares of common stock at an exercise price of $325.07 per share, expiring on March 2, 2036. The option and RSUs vest over multi‑year schedules tied to her continued service.
Alnylam Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on May 20, 2026 at 10:30 a.m. Eastern Time. Holders of record as of March 25, 2026 can participate online and vote.
Stockholders will elect three Class I directors—Stuart Arbuckle, CEO Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D.—for terms ending in 2029, cast an advisory say‑on‑pay vote on executive compensation, and ratify PricewaterhouseCoopers LLP as independent auditors for 2026.
The proxy highlights Alnylam’s classified board structure, majority voting policy, and a board composed of nine independent and one management director, with a mix of biopharma, financial, governance and scientific expertise. It also details ESG and corporate responsibility initiatives, including patient access programs, climate and data governance work, and a refreshed director compensation mix of cash, stock options and RSUs.
Alnylam Pharmaceuticals Inc: Amendment No. 10 to a Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned of Alnylam common stock and 0% ownership as disclosed in the form. The filing includes a statement that Vanguard reorganized certain subsidiaries on January 12, 2026, and those entities will report separately following SEC Release No. 34-39538.
ALNYLAM PHARMACEUTICALS, INC. EVP and Chief R&D officer Pushkal Garg reported open-market sales of 4,713 shares of common stock on March 4–5, 2026, at prices generally in the low-to-mid $320s per share, in multiple transactions.
The filing notes that some shares were automatically sold by the company to cover minimum statutory tax withholding when restricted stock units vested, and that certain transactions were executed under a Rule 10b5-1 trading plan adopted on November 20, 2025. Following these sales, Garg directly held 18,693 common shares, with additional indirect holdings reported through a managed account and a trust, the latter with a disclaimer of beneficial ownership.